Yonsei Med J.  2015 Jan;56(1):307-308. 10.3349/ymj.2015.56.1.307.

Intralesional 3% Sodium Tetradecyl Sulfate for Treatment of Cutaneous Kaposi's Sarcoma

• Kim JY
• Kim JS
• Kim MH
• Park BC
• Hong SP

• KMID: 2352823
• DOI: http://doi.org/10.3349/ymj.2015.56.1.307

Abstract

No abstract available.

MeSH Terms

Aged, 80 and over
Female
Humans
Injections, Intralesional
Sarcoma, Kaposi/*drug therapy
Skin Neoplasms/*drug therapy
Sodium Tetradecyl Sulfate/*administration & dosage/*therapeutic use
Sodium Tetradecyl Sulfate

Reference

1. Ramírez-Amador V, Esquivel-Pedraza L, Lozada-Nur F, De la Rosa-García E, Volkow-Fernández P, Súchil-Bernal L, et al. Intralesional vinblastine vs. 3% sodium tetradecyl sulfate for the treatment of oral Kaposi's sarcoma. A double blind, randomized clinical trial. Oral Oncol. 2002; 38:460–467.

2. Di Lorenzo G. Update on classic Kaposi sarcoma therapy: new look at an old disease. Crit Rev Oncol Hematol. 2008; 68:242–249.

3. Célestin Schartz NE, Chevret S, Paz C, Kerob D, Verola O, Morel P, et al. Imiquimod 5% cream for treatment of HIV-negative Kaposi's sarcoma skin lesions: A phase I to II, open-label trial in 17 patients. J Am Acad Dermatol. 2008; 58:585–591.

4. Muzyka BC, Glick M. Sclerotherapy for the treatment of nodular intraoral Kaposi's sarcoma in patients with AIDS. N Engl J Med. 1993; 328:210–211.

5. Benomar S, Boutayeb S, Benzekri L, Errihani H, Hassam B. Kaposi's sarcoma responding to topical imiquimod 5% cream: a case report. Cases J. 2009; 2:7092.